Phase 1 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your Body Mass Index (BMI) is between 18 and 32, and you weigh at least 45 kg (about 99 lbs)
- You have been diagnosed with Alzheimer's disease (AD) dementia based on recognized medical criteria, which may include memory-related or other thinking-related symptoms
- There is supporting evidence from past medical records or recent tests showing the presence of amyloid (a protein linked to Alzheimer's disease) in your body
- Your Alzheimer's disease is considered mild, shown by specific scores on two standard memory and thinking tests (a Clinical Dementia Rating score of 0.5 or 1, and a Mini-Mental State Examination score between 20 and 30)
Who may not be able to join:
- You have a significant brain or thinking disorder other than Alzheimer's disease, as judged by the study doctor
- You have a significant psychiatric (mental health) condition
- You have any unstable or poorly managed condition affecting organs such as your lungs, heart, digestive system, liver, or blood, which the study doctor believes could affect the study
- You have been diagnosed with cancer in the last 5 years (some exceptions may apply, such as certain low-risk or fully treated skin cancers — confirm with trial site)
- You have previously received any treatment designed to target amyloid or tau proteins in the brain, including certain types of immunotherapy vaccines (some exceptions may apply for certain participants — confirm with trial site)
- You have previously received gene therapy of any kind
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Monitor, Denali Therapeutics
Phone: Email:
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.